Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Acute promyelocytic leukaemia, drawn from the whole corpus: 1 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Early haemorrhagic death before treatment starts, especially where diagnosis is slow.
Treatment of variant RARA fusions that do not respond to arsenic or retinoic acid.
Whether high-risk patients can also be spared chemotherapy.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 12 changes by month →When this page itself was last checked or edited.
Newly diagnosed low-risk APL with tretinoin
A milestone in how this cancer is treated.
All-trans retinoic acid plus arsenic trioxide was superior to retinoic acid plus chemotherapy for event-free and overall survival in non-high-risk APL.
A milestone in how this cancer is treated.
APL